BTIG Raises Liquidia Price Target Following YUTREPIA Approval

On Monday, June 2, BTIG analysts raised the price target for Liquidia Corporation (NASDAQ:LQDA) from $37 to $45 and kept a “Buy” rating.

This decision came after the full FDA approval of YUTREPIA inhalation powder for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The drug is now available in specialty pharmacies. BTIG noted that the annualized WAC price for YUTREPIA was set at $317,000.

An aerial view of a biopharmaceutical manufacturing plant, signifying the company’s expansive operations.

BTIG expects the market to focus on the pending temporary restraining order filed by United Therapeutics. However, the firm believes that there is a low chance that Liquidia Corporation (NASDAQ:LQDA) will be stopped from selling YUTREPIA now that it has full FDA approval. The court has also denied the request for preliminary injunction and a temporary restraining order by United Therapeutics, which cleared the path for the full commercial launch of YUTREPIA.

The increase in the price target for Liquidia Corporation (NASDAQ:LQDA) also reflects improved probabilities for YUTREPIA’s success in treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The analysts increased the probability of success from 95% to 99% and lowered the discount rate from 20% to 17.5%.

Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company that focuses on developing and commercializing therapies for rare cardiopulmonary diseases.

While we acknowledge the potential of LQDA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LQDA and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 11 Stocks That Will Bounce Back According To Analysts and 11 Best Stocks Under $15 to Buy According to Hedge Funds.

Disclosure: None.